Core Viewpoint - Vison Pharma-B (02561) experienced a stock price increase of over 7% during trading, currently up by 3.64% at HKD 31.88, following news of a collaboration with Anke Bio [1] Group 1: Company Developments - Anke Bio recently disclosed progress in its collaboration with Vison Pharma regarding the growth-promoting hormone Longpei, which is expected to receive approval soon [1] - On July 14, Anke Bio announced a strategic cooperation framework agreement with Vison Pharma to promote the market penetration of Longpei in China [1] - Vison Pharma's core product, Longpei, had its application for market approval accepted by the National Medical Products Administration of China in March 2024, with expectations for market approval in the second half of 2025 [1]
港股异动 | 维昇药业-B(02561)盘中涨超7% 公司核心产品隆培促生长素即将获批